At a glance
ClinicalIndex Comparison RecordN/ACompleted· 460 enrolled
Drug / intervention
SC anti-TNFother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subcutaneous Anti-tnf-αlpha In Rheumatoid Arthritis: Analyze The Correlation Between Objective Measures Of Disease Activity And Safety And A Subjective Measure Such As Patient Beliefs About A Medicine
In Brief
An observational study evaluating SC anti-TNF for Rheumatoid Arthritis. Completed, enrolled 460 participants across 1 site.
Detailed Summary
It can be assumed that there is a link between what the patient feels and thinks about his medication and objective measures of disease activity and safety.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedSep 2011
Primary CompletionDec 2013
Study CompletionJan 2015
TodayJul 2026
First PostedSep 13, 2011
Enrollment StartOct 1, 2010
Primary CompletionDec 1, 2013
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 14.8 years ago
Interventions
SC anti-TNFother
Subcutaneous (SC) anti-TNF